Redeye lowers its forecasts and Base Case following a Q3 report with softer ARR growth than expected. However, management is taking several initiatives indicating stronger growth in 2022 and onwards, and we leave our Bull Case unchanged.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases